Linagliptin CAS:668270-12-0 Mai Kaya na Masana'anta

Linagliptin (sunayen kasuwanci Tradjenta da Trajetna) wani maganin hana dipeptidyl peptidase-4 (DPP-4) ne wanda Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da shi a watan Mayu na 2011 don maganin ciwon suga na nau'in 2 tare da abinci da motsa jiki. An bayyana Linagliptin (BI-1356) a matsayin mai ƙarfi mai zaɓi sosai, mai saurin rage gudu kuma mai hana DPP-4 na dogon lokaci. Linagliptin ya samo asali ne daga ƙoƙarin ingantawa na masu hana DPP-4 na xanthine tare da gano gubar farko daga kamfen ɗin HTS.

Yi oda ko Nemi Farashi

Cikakken Bayani game da Samfurin

Alamun Samfura

Aikace-aikace da Tasiri

Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) magani ne mai hana dipeptidyl peptidase-4 ta baki, mai zaɓe sosai kuma shine wakili na farko a cikin ajin sa da aka cire shi ta hanyar da ba ta cikin koda ba. Ana ba da shawarar Linagliptin sau ɗaya a rana don maganin manya masu ciwon suga na nau'in 2. Linagliptin yana aiki don rage matakan glucose na jini ta hanyar hana enzyme DPP-4, don haka yana hana lalacewar hormones na incretin (peptide-like glucagon-1 [GLP-1] da insulinotropic peptide mai dogara da glucose) da kuma rage yawan tafiya bayan cin abinci.

Samfurin Samfuri

Shirya Samfurin:

Ƙarin Bayani:

Tsarin aiki	C25H28N8O2
Gwaji	99%
Bayyanar	Foda fari
Lambar CAS	668270-12-0
shiryawa	25KG
Rayuwar shiryayye	Shekaru 2
Ajiya	A adana a wuri mai sanyi da bushewa
Takardar shaida	ISO.